Please login to the form below

Not currently logged in
Email:
Password:

Pfizer's Wyeth acquisition gets EC go ahead

Pfizer has announced that the EC has cleared its $68bn purchase of Wyeth

Pfizer has announced that the European Commission(EC) (under the European Union Merger Regulation authorisation process) has cleared its $68bn purchase of Wyeth.

"We are pleased to have achieved another significant milestone for the pending acquisition with the EC's approval of the transaction," said Amy Schulman, senior vice president and general counsel of Pfizer.

Pfizer agreed to buy Wyeth in January, but approvals from regulators and governments on several continents are required due to the size of the businesses involved. Pfizer has also said that the Chinese Ministry of Commerce has extended its review of the deal beyond the initial 30 days. Meanwhile, in the US, a 90-day regulatory review continues.

Wyeth shareholders are scheduled to vote on the merger today and the deal is expected to close at the end of the third quarter or during the fourth.

20th July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics